Form D · Biotechnology
ARCION THERAPEUTICS, INC.
Baltimore, MD · CIK 0001421000
Offering snapshot reported Oct 1, 2012 · SEC filing
- Reported sold
- $1.5M Indefinite offering
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 31, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 1, 2012 | Initial | $1,500,000 | No comparison | 3 | SEC filing |
| Nov 1, 2010 | Initial | $400,000 | No comparison | 3 | SEC filing |
| Apr 22, 2010 | Initial | $1,250,000 | No comparison | 3 | SEC filing |
| Feb 1, 2010 | Initial | $5,000,000 | No comparison | 3 | SEC filing |
| Dec 10, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-184847
Source: Form D, filed Oct 1, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kerrie Brady | Executive |
| James Campbell | Director, Executive |
| David Collier | Director |
| Cynthia Mc Cormick | Director |
| Arnold Oronsky | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2400 Boston Street, Suite 330
Baltimore, MD, 21224
Baltimore, MD, 21224